Metagenomi Therapeutics, Inc.
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $25.2M
- Net income
- -$87.9M
- Total assets
- $221.1M
- Market cap
- $48.2M
- Operating margin
- -380.9%
- Net margin
- -348.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $25.2M
- Operating expenses
- $121.2M
- Operating income
- -$96.0M
- Income tax
- -$58.0K
- Net income
- -$87.9M
- EPS (basic)
- $-2.36
- EPS (diluted)
- $-2.36
Balance sheet
- Total assets
- $221.1M
- Current assets
- $165.5M
- Total liabilities
- $62.5M
- Current liabilities
- $22.9M
- Shareholders’ equity
- $158.6M
Cash flow
- Operating cash flow
- -$88.9M
- Investing cash flow
- $103.5M
- Financing cash flow
- -$356.0K
- Net cash flow
- $14.3M
Statements via Polygon.io (SEC filings)
- Market cap
- $48.2M
- EPS (diluted)
- $-2.36
- Shares outstanding
- 37.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 9, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $87.9M in FY2025.
- Revenue declined 52% from FY2024 to FY2025.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Metagenomi Therapeutics, Inc..
Write a review
News about Metagenomi Therapeutics, Inc.
News & sentiment via Polygon.io
